ASCO GI: Targeted Agent Slows Neuroendocrine Tumors

ORLANDO -- Patients with progressive pancreatic neuroendocrine tumors lived twice as long without progression when treated with sunitinib (Sutent) compared with placebo, data from a French clinical trial showed.

Medpage Today: http://medpagetoday.com
Online CME - Continuing medical education: http://www.medpagetoday.com/cme/
Latest medical news: http://www.medpagetoday.com/latest/

The MedPage Today app:
iOS: https://goo.gl/JKrkHq
Android: https://play.google.com/store/....apps/details?id=com.

MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageToday
Medpage Today on Facebook: https://www.facebook.com/MedPageToday

Median overall survival had not been reached in the sunitinib arm, but sunitinib treatment was associated with a 60% reduction in hazard ratio compared with placebo. More than 90% of patients in the sunitinib group remained alive at six months, Eric Raymond, MD, reported here at the Gastrointestinal Cancers Symposium.